<DOC>
	<DOCNO>NCT02367937</DOCNO>
	<brief_summary>The aim study evaluate effect PRC-4016 steady state pharmacokinetics ( PK ) cytochrome P450 ( CYP ) 3A substrate ( midazolam , simvastatin ) , CYP2C9 substrate ( omeprazole ) CYP2C19 substrate ( flurbiprofen ) healthy male/female subject .</brief_summary>
	<brief_title>PRC-4016 ( Icosabutate ) Phase I Drug-drug Interaction Study</brief_title>
	<detailed_description>Day 1 : Subject receive single oral dos 2.5 mg midazolam , 20 mg omeprazole 50 mg flurbiprofen morning Day 2 : Subject receive single oral dose 40 mg simvastatin morning Day 2 . Day 4 : Subjects commence multiple-dose regimen PRC-4016 ( 600 mg daily ) 11 day . Day 12 : Subjects give single oral dos 2.5 mg midazolam , 20 mg omeprazole 50 mg flurbiprofen co-administered 600 mg PRC-4016 . Day 13 , subject give single oral dose 40 mg simvastatin co-administered 600 mg PRC-4016 . All subject return post-study visit 7 10 day final dose .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>male females ethnic origin age 1860 year BMI 8.0 35.0 kg/m2 generally good health sign informed consent male female willing use appropriate contraception recent blood donation recent blood receive high consumption alcohol high consumption og tobacco subject engage heavy exercise last two week prescribe systemic topical medication take recently , supplements/remedies interfere study procedure safety medication know alter drug absorption elimination abnormal hearth rate blood pressure significant history drug allergy hypersensitivity treatment ingredient significant medical history physical finding pregnant lactate Poor metabolizers CYP2C9 CYP2C19 subject previously take part withdrawn study subject accord investigator participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Phase I drug-drug interaction</keyword>
</DOC>